Tyra Biosciences, Inc.

NASDAQ•TYRA

CEO: Dr. Todd Harris Ph.D.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2021-09-15

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

Contact Information

2656 State Street, Carlsbad, CA, 92008, United States

619-728-4760

tyra.bio

Market Cap

$1.88B

P/E (TTM)

-17.4

Dividend Yield

52W High

$40.65

52W Low

$8.75

52W Range

82%

Rank56Top 81.7%

2.5

F-Score

Modified Piotroski Analysis

Based on 6-year fundamentals

Weak • 2.5 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.57+0.00%

4-Quarter Trend

FCF

-$23.68M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Pipeline Advances Dabogratinib Trials Advancing oral dabogratinib in three Phase 2 trials (LG-UTUC, IR NMIBC, ACH) under "dabogratinib 3x3" strategy.

Operating Expenses Increased Significantly Total operating expenses rose $28.5M to $132.7M in 2025, driven by $22.8M R&D spending increase.

Net Loss Widened Substantially Net loss reached $(119.9)M in 2025, compared to $(86.4)M loss reported in the prior year period.

Cash Runway Through 2027 Current cash, equivalents, and securities of $256.0M fund operations through at least 2027 under current plan.

Risk Factors

Significant Capital Required Continues Substantial additional capital needed to achieve goals; expects to incur significant net losses for foreseeable future.

Early Stage Development Hurdles Organization has never completed clinical trials or obtained marketing approval, making evaluation difficult for investors.

Reliance on Third-Party Contractors Dependence on third parties for manufacturing and clinical trial execution increases risk of delays or supply disruption.

Competition Landscape Intensifies Faces intense competition from larger, better-funded firms; success hinges on efficacy and favorable safety profile.

Outlook

Key Clinical Data Expected 2026 Anticipate reporting initial three-month CR data for SURF302 and safety sentinel results for BEACH301 by H1/H2 2026.

Advance Toward Registrational Trials Success in current Phase 2 studies expected to advance dabogratinib toward three potential registrational trials.

Expanding Pipeline with Other Assets Evaluating TYRA-430 in Phase 1 HCC trial and TYRA-200 in FGFR2-resistant ICC Phase 1 trial.

Future Financing Needs Uncertain Current cash supports operations through 2027; future development requires securing additional financing on favorable terms.

Peer Comparison

Revenue (TTM)

IOVA

$263.50M

+60.6%

AKBA

$236.19M

+47.5%

VALN

$197.09M

+3.0%

Gross Margin (Latest Quarter)

PRME

4698.2%

-3591.0pp

IOVA

215.9%

+65.9pp

NBTX

100.0%

+0.0pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
TERN	$4.77B	-51.3	-20.0%	0.1%
ERAS	$3.08B	-22.5	-34.5%	11.9%
DAWN	$2.22B	-20.7	-23.4%	0.5%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:Apr 30, 2026

EPS:-$0.58

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data